Faucher FA, Gannier FE, Lignon JM, Cosnay P, Malécot CO. Roles of PKA, PI3K, and cPLA2 in the NO-mediated negative inotropic effect of ␤2-adrenoceptor agonists in guinea pig right papillary muscles. Am J Physiol Cell Physiol 294: C106-C117, 2008. First published October 17, 2007 doi:10.1152/ajpcell.00231.2007.-Although ␤2-adrenoceptors represent 15-25% of ␤-adrenoceptors in the guinea pig heart, their functionality is controversial. We assessed the inotropic effects of ␤2-adrenoceptor partial agonists in right papillary muscles. Salbutamol induced a small but significant concentration-dependent negative inotropic effect (NIE, Ϫ5% at 60 nM) followed by a moderate positive inotropic effect (ϩ36% at 6 M) due to activation of ␤ 1-adrenoceptors. In the presence of 4 M atenolol, the concentration-dependent NIE (Ϫ12% at 6 M) was biphasic, best described by a double logistic equation with respective EC50 values of 3 and ϳ420 nM, and was insensitive to SR59230A. In muscles from pertussis toxin-treated guinea pigs, the salbutamol-induced positive inotropic effect was sensitive to low concentrations of ICI-118551 in an unusual manner. Experiments in reserpinized animals revealed the importance of the phosphorylation-dephosphorylation processes. PKA inhibition reduced and suppressed the effects obtained at low and high concentrations, respectively, indicating that its activation was a prerequisite to the NIE. The effect occurring at nanomolar concentrations depended upon PKA/phosphatidylinositol 3-kinase/ cytosolic phospholipase A 2 (cPLA2) activations leading to nitric oxide (NO) release via the arachidonic acid/cyclooxygenase pathway. NO release via PKA-dependent phosphorylation of the receptor was responsible for the inotropic effect observed at submicromolar concentrations, which is negatively controlled by cPLA 2. The possibility that these effects are due to an equilibrium between different affinity states of the receptor (G s/Gi coupled and Gi independent with different signaling pathways) that can be displaced by ICI-118551 is discussed. We conclude that ␤ 2-adrenoceptors are functional in guinea pig heart and can modulate the inotropic state.
␤-ADRENOCEPTORS play a fundamental role in the regulation of the cardiac contractile machinery, in part because of the predominance of sympathetic neuronal influences (45) . In normal physiological conditions, cardiac stimulatory catecholamine effects are mostly mediated by ␤ 1 -adrenoceptors via their coupling to G s protein and activation of cAMP-dependent PKA signaling pathways. ␤ 2 -Adrenoceptors, although present at a lower density (the ␤ 1 -to ␤ 2 -adrenoceptor ratio in the human heart is ϳ70 -80%/30 -20%; Ref. 6) , are more tightly coupled to the G s protein and thus induce a more pronounced activation of the adenylate cyclase (7) . However, their inotropic effects are less than expected because of their localization in caveolae and the presence of a barrier of phosphodiesterases around them that limits the diffusion of cAMP resulting from their activation inside the cell (for review, see Ref. 18) . Besides the G s /cAMP-dependent PKA signaling pathway, ␤ 2 -adrenoceptors can activate G i protein-dependent pathways (22, 50, 58) . For example, phosphatidylinositol 3-kinase (PI3K; Ref. 26) and cytosolic phospholipase A 2 (cPLA 2 ; Ref. 1) have been shown to functionally restrict in a pertussis toxin (PTX)-sensitive manner the ␤ 2 -adrenoceptor-mediated cAMP/PKA signaling in the rat heart. Thus this coupling limits the G smediated effect, especially the contractile response, an effect that may be of particular importance in pathological situations such as heart failure. Indeed, heart failure and aging are characterized by an increase in sympathetic activity leading to a decrease of functional responsiveness of cardiac ␤-adrenoceptors due to a diminution in ␤ 1 -adrenoceptor density and uncoupling of ␤ 2 -adrenoceptors from the G s protein-adenylate cyclase pathway. Albeit controversial, an increased coupling of ␤ 2 -adrenoceptors to the G i protein has also been reported to occur (for review, see Refs. 7, 8) , possibly leading to a more pronounced impairment of adrenergic responses.
Although the existence of ␤ 2 -adrenoceptors in the guinea pig heart has been demonstrated by radioligand binding studies, their functionality is still a matter of controversy. Several studies argue against a functional role of ␤ 2 -adrenoceptors. In fact, the effects obtained at rather high concentrations of agonist are either blocked by the ␤ 1 -adrenoceptor antagonist atenolol or sensitive to the specific ␤ 2 -adrenoceptor antagonist ICI-118551 at concentrations known to also affect ␤ 1 -adrenoceptors (23, 40, 54) . However, other studies reported that ␤ 2 -adrenoceptor activation induced an increase in heart rate (31, 52) and L-type calcium current of isolated ventricular cells (30, 36) and that these effects were sensitive to low concentrations of ICI-118551. The results of the former studies against a functional role of ␤ 2 -adrenoceptors are surprising since their population in guinea pig hearts represents, as in the human heart, a nonnegligible proportion of total ␤-adrenoceptors, i.e., 15-36% in the ventricles (31, 52 ) and 15-25% in the atria (37, 52) .
We hypothesize that these discrepancies might be explained by the dual coupling of ␤ 2 -adrenoceptors to G s and G i proteins leading to activation of different signaling pathways with opposing effects. Indeed, depending on the preponderant pathway, inotropic responses may be positive (G s -dominant path-way), negative (G i -dominant pathway), or even absent. Moreover, as shown for ␤ 3 -adrenoceptors (for review, see Ref. 19 ), ␤ 2 -adrenoceptor activation can induce nitric oxide (NO) release (15, 27) and thus possibly a direct negative inotropic effect (although not yet described). On that basis, we have reinvestigated the functionality of ␤ 2 -adrenoceptor activation in guinea pig right papillary muscles by studying their potential inotropic effects. Surprisingly, we found that ␤ 2 -adrenoceptor agonists can induce at low concentrations a significant ICI-118551-sensitive negative inotropic effect when ␤ 1 -adrenoceptor activation is prevented by atenolol, an effect that cannot be ascribed to nonspecific activation of ␤ 3 -adrenoceptors. We show here the dual G s /G i coupling of guinea pig ␤ 2 -adrenoceptors and the predominant role of NO release in the biphasic negative inotropic effect of salbutamol and investigate the underlying signaling pathways.
MATERIALS AND METHODS
Animals and experimental protocols. Studies were performed on male Dunkin-Hartley guinea pigs (250 -400 g; Charles River Laboratories, L'Arbresle, France) housed in University standard animal care facilities (agreement C37-261-4). They were exposed to a standard 12:12-h light-dark cycle with ad libitum access to food and water. The experimental procedures were performed in accordance with European guidelines [authorizations: 7741 (C. O. Malécot), 37-045 (F. E. Gannier), 7320 (J. M. Lignon)] and with the Regional Centre-Limousin ethical committee for animal experimentation.
After heparinization (5 IU/g ip), guinea pigs were humanely killed by cervical dislocation to avoid any interaction with anesthetics. After quick removal of the heart and retrograde perfusion through the aorta, papillary muscles from the right ventricle were carefully dissected under a microscope in normal physiological saline at room temperature and mounted in a 5-ml thermostated and oxygenated glass experimental chamber maintained at 37°C. The base of the muscle was fixed in the bottom of the chamber coated with Sylgard (Dow Corning, Seneffe, Belgium) with minutien pins. The tendinous tip was connected via a small hook to a Pioden dynamometer UF1 forcedisplacement transducer (Pioden Controls, Canterbury, UK) mounted on a three-dimensional micromanipulator (Narishige International, London, UK). Muscles were stretched to ϳ80 -90% of length yielding maximum force and allowed to equilibrate before the start of the experiment until stable contraction amplitude was obtained. The contractions elicited by field stimulation (2 Hz, 1-ms suprathreshold rectangular pulse typically of 3.5-4 V), low-pass filtered at 40 Hz, were visualized on a digital oscilloscope (Tektronix TDS310, Tektronix, Les Ulis, France) and recorded both on a chart paper (GRASS 7400, Astro-Med, Trappes, France) and on magnetic tape (DAT DTR 1202, Bio-Logic Science Instruments, Claix, France) for further offline analysis with IOX software (version 1.7.0; EMKA Technologies, Paris, France).
During the experiments, the muscle was continuously superfused at 37°C with Tyrode solution at a constant flow rate (1 ml/min) maintained by a peristaltic pump (Minipuls 2, Gilson International, Roissy en France, France), except for the establishment of the cumulative concentration-response curves, during which the perfusion was stopped. A stabilization period, usually of 10 min, was then necessary for the muscle to reach a new stable contraction amplitude before the first concentration of ␤2-agonist was added. When used, antagonists of ␤-adrenoceptors and inhibitors were directly added to the Tyrode solution at the final concentration and allowed to equilibrate for 10 -15 min, except for N -nitro-L-arginine methyl ester (L-NAME; 20 min). The Tyrode solution contained (in mM) 120 NaCl, 5.4 KCl, 1 MgCl 2, 2 CaCl2, 0.6 NaH2PO4, 25 NaHCO3, 5 pyruvic acid, 0.05 ascorbic acid, and 11 glucose, pH adjusted to 7.35 (95% O2-5% CO2).
Drugs and reagents. Reserpine, salbutamol hemisulfate, terbutaline hemisulfate, procaterol hydrochloride, (Ϯ)isoproterenol hydrochloride, ICI-118551 hydrochloride, atenolol, H-89 dihydrochloride, wortmannin, indomethacin, nordihydroguaiaretic acid (NDGA) and L-NAME hydrochloride were purchased from Sigma (Sigma-Aldrich Chimie, Saint Quentin Fallavier, France). SR59230A hydrochloride, okadaic acid sodium salt, and arachidonyl trifluoromethyl ketone (AACOCF 3) were obtained from Tocris (Tocris Bioscience; FisherBioblock, Illkirch, France). All drugs, prepared as stock solutions in distilled water kept at Ϫ20°C, were freshly diluted in Tyrode solution each day before use. When a vehicle (DMSO or ethanol) was used to prepare stock solutions, control experiments were carried out in the presence of equivalent final concentrations of the vehicle. No differences were observed in the concentration-response curves to salbutamol in the presence and absence of vehicle alone. All other chemicals were also purchased from Sigma.
Guinea pig treatments. To reduce the amount of circulating catecholamines, seven guinea pigs (mean wt 338.6 Ϯ 10.4 g) received 24 h before death an intraperitoneal injection of freshly prepared reserpine (brought into solution in double-distilled water containing 2% glacial acetic acid) at a dose of 1 mg/kg. This procedure has been reported to cause an almost 95% depletion of endogenous catecholamines (53) . All animals presented a significant weight loss at the time of the experiment (11.0 Ϯ 1.2% of initial body wt).
To partially inactivate G i proteins, nine guinea pigs (mean wt 296.6 Ϯ 3.6 g) received an intraperitoneal injection of 100 g/kg PTX (Calbiochem, Merck Chemicals, Nottingham, UK). The choice of the concentration used was based on the experiments of Hopwood et al. (25) on guinea pig papillary muscles. To reduce mortality and weakness (2 died after 72-h treatment, and 1 was very weak with complete loss of muscular tone), guinea pigs were killed between 71 and 72 h after injection and had a mean weight of 297.6 Ϯ 5.8 g at that time. Four animals presented a significant weight loss, which represented 7.5 Ϯ 1.3% of their initial body weight. Efficacy of the treatment was assessed by the reduction of the antiadrenergic effect of acetylcholine (see Fig. 3A ): only muscles presenting a significant reduction were included in the study.
Data expression and statistics. All results are expressed as means Ϯ SE obtained on n muscles from different guinea pigs. To establish the concentration-response curves to ␤ 2-adrenoceptor agonists, contraction amplitudes measured with IOX software are expressed as percentage of the control contraction amplitude (measured in Tyrode solution in the absence or presence of either ␤-adrenoceptor antagonists or inhibitors of key enzymes) before agonist application, taken as 100%. The following customized logistic equations (simple: Eq. 1; double negative: Eq. 2; double positive-negative: Eq. 3) were adjusted to the data points to determine maximum inotropic effects of agonists and their EC 50 with OriginPro 7.0 software (OriginLab, Northampton, MA):
with 
RESULTS
Inotropic effects of ␤ 2 -adrenoceptor agonists and selectivity. The inotropic effects of increasing concentrations of salbutamol (0.4 nM to 6 M) are illustrated in Fig. 1A . At concentrations between 0.4 nM and 0.4 M, salbutamol surprisingly induced a small but statistically significant concentration-dependent negative inotropic effect reaching Ϫ4.9 Ϯ 0.9% (n ϭ 14) at 60 nM. The EC 50 value of 6.9 Ϯ 3.2 nM is in accordance with that for activation of ␤ 2 -adrenoceptors reported in the literature (i.e., Refs. 9, 57). At higher concentrations, a more classical positive inotropic effect reaching ϩ36.3 Ϯ 4.9% at 6 M was observed, associated with a slight reduction in the time to peak tension (not shown).
Because agonists can lose their specificity when used at high concentrations, concentration-response curves to salbutamol were made in the presence of a ␤ 1 -adrenoceptor antagonist. In the presence of 200 nM atenolol, the negative inotropic effect was more pronounced (Ϫ12.3 Ϯ 2.5% at 60 nM, EC 50 of 4.9 Ϯ 1.2 nM; n ϭ 9) whereas the positive inotropic effect was reduced (ϩ19.3 Ϯ 5.9% at 6 M). At a higher concentration of atenolol (4 M), salbutamol induced only a statistically significant (P Ͻ 0.01) concentration-dependent negative inotropic effect (Fig. 1B) , which reached a maximum of Ϫ11.7 Ϯ 0.9% at 6 M (n ϭ 19). This suggests that the positive inotropic effect of salbutamol resulted from activation of ␤ 1 -adrenoceptors. The absence of effects of cumulative injections of Tyrode solution alone over the time needed to build a concentrationresponse curve (Fig. 1B) ruled out a possible rundown of the contraction amplitude (during the establishment of the concentration-response curves). Moreover, all these effects of salbutamol were fully reversible on washout.
The shape of the mean concentration-response curve in the presence of 4 M atenolol suggested that the negative inotropic effect of salbutamol might be biphasic. Adjusting the data with a simple logistic equation gave an EC 50 of 19.9 Ϯ 5.8 nM and a slope factor of 0.5 Ϯ 0.05, far below unity. With a double logistic equation, the two EC 50 values (3.0 Ϯ 0.6 nM and 418.1 Ϯ 157.9 nM; n ϭ 19) were statistically different and the slope factor was 0.9 Ϯ 0.1 (see MATERIALS AND METHODS), a value close to unity. As shown in Table 1 , both fits appeared quite good when the R 2 values were considered. However, comparison of the two models with Fisher's test and AICc indicated that the double logistic model has a highly significant (P Ͻ 0.002; Table 1 ) lower sum of squares from least-squares nonlinear regression (SSR) and a lower AICc. Calculation of the information ratio (ratio of the probabilities for each model) indicates that the model double logistic is 85 times more likely to be correct than the model simple logistic (Table 1) . Therefore, two distinct mechanisms, each one having different threshold and sensitivity, might be involved in the biphasic negative inotropic effect of salbutamol.
To determine whether the observed negative inotropic effect of salbutamol was specific to this molecule or a more common feature of short-acting ␤ 2 -adrenoceptor agonists, concentration-response curves to other agonists were made in the presence of 200 nM atenolol. Terbutaline and procaterol also induced a biphasic negative inotropic effect (Fig. 1C) of Ϫ17.5 Ϯ 3.4% (at 2 M) and Ϫ14.9 Ϯ 5.2% (maximum at 0.6 M), respectively, with EC 50 values of 1.9 Ϯ 1.2 and 110.9 Ϯ 91.5 nM (n ϭ 7) and of 3.1 Ϯ 1.5 and 45.1 Ϯ 11.3 nM (n ϭ 5). Therefore, under our experimental conditions, we can conclude that short-acting ␤ 2 -adrenoceptor partial agonists induce a biphasic negative inotropic effect.
To test an eventual implication of ␤ 3 -adrenoceptors in the biphasic negative inotropic effect of salbutamol, concentrationresponse curves were determined in the additional presence of SR59230A, a selective ␤ 3 -adrenoceptor antagonist. At a concentration of 200 nM, which should block almost 98% of ␤ 3 -adrenoceptors with minimal effects on ␤ 2 -adrenoceptors (33), the concentration-response curves to salbutamol determined in nine muscles (Fig. 1D) were not significantly affected (Table 3) . Therefore, ␤ 3 -adrenoceptors do not appear to be involved in the negative inotropic effect of salbutamol.
Effect of ICI-118551 on negative inotropic effect. The effect of ICI-118551, a selective ␤ 2 -adrenoceptor antagonist, was examined in the presence of 4 M atenolol. Figure 2 shows that, in the presence of 40 nM ICI-118551, salbutamol induced a positive inotropic effect with an EC 50 of 1.9 Ϯ 0.4 nM (n ϭ 5) similar to that of the first negative component in control conditions (Table 2 ). It was followed at higher concentrations by a negative inotropic effect, as in control conditions (EC 50 of 316.9 Ϯ 61.4 nM). These results indicate that ␤ 2 -adrenoceptor activation is involved in the negative component induced by nanomolar concentrations of salbutamol.
To determine whether or not ␤ 2 -adrenoceptors are also involved in the second component of the negative inotropic effect, ICI-118551 concentration was raised to 400 nM to SSR, sum of squares from least-squares nonlinear regression; DF, degrees of freedom; R 2 , coefficient of determination; P, probability that chosen model is correct. F ϭ ͓(SSR1 Ϫ SSR2)/SSR2͔/͓(DF1 Ϫ DF2)/DF2͔ ϭ 29.91 (at 0.05 level, critical F value is F7,5 ϭ 6.85; thus P ϭ 0.00156).
achieve Ͼ99% blockade of the receptors, given the pK i values determined by Molenaar and Summers (37) in guinea pig atria (8.87-8.4 ). In the presence of this high concentration, the biphasic negative inotropic effect of salbutamol (which was suppressed at a lower concentration of ICI-118551) was surprisingly restored, but with a concentration dependence shifted to the right (Fig. 2) . Albeit small, the right shift of the first component (EC 50 of 4.7 Ϯ 1.2 nM and 12.9 Ϯ 3.4 nM in the absence and presence of ICI-118551, respectively; n ϭ 8) is nevertheless statistically significant (Table 2) . On the other hand, although less than expected, the second component is markedly right shifted (EC 50 increased ϳ27 times from 224.8 Ϯ 50.4 nM to 6.2 Ϯ 1.5 M; n ϭ 8; apparent pA 2 of 7.82). Although at this concentration ICI-118551 should also bind onto ␤ 1 -adrenoceptors, we found that these receptors were functionally not significantly affected since the EC 50 of the concentration-response curve to isoproterenol was not changed (not shown). Moreover, the concentration of atenolol used during these experiments (4 M) is sufficient to already induce Ͼ95% block of ␤ 1 -adrenoceptors. Thus an additional effect of ICI-118551 on these receptors is probably irrelevant. Therefore, these results strongly suggest that ␤ 2 -adrenoceptors are likely involved in both components of the negative inotropic effect of salbutamol.
Role of G i protein coupling and antagonism by ICI-118551. Since G s -coupled ␤ 2 -adrenoceptors can simultaneously activate a pathway that leads to functional inhibition via a PTXsensitive G i protein (55), we hypothesized that the negative inotropic effect of salbutamol resulted from the coupling of the receptors to G i proteins. The effect of salbutamol was therefore tested in papillary muscles from PTX-treated guinea pigs. PTX pretreatment did not affect the G s -mediated positive inotropic effect induced by 50 nM isoproterenol alone [control: ϩ266.7 Ϯ 66.9% (n ϭ 7); PTX-treated: ϩ244.0 Ϯ 49.8% (n ϭ 8); not shown] but markedly reduced the antiadrenergic effect of acetylcholine as illustrated in Fig. 3A . Only half of the papillary muscles presenting a marked reduction of the antiadrenergic effect of acetylcholine were stable enough in the presence of salbutamol to perform reliable measurements. Figure 3B shows that when G i proteins were inactivated, salbutamol alone induced only a concentration-dependent positive inotropic effect (ϩ5.8 Ϯ 0.6%, n ϭ 4) with an EC 50 of 0.101 Ϯ 0.007 nM, 10 times lower than in papillary muscles from nontreated guinea pigs, as expected for a dual G s /G i coupling of the ␤ 2 -adrenoceptor in nontreated animals. The results obtained in the presence of 40 nM ICI-118551 were unexpected since the salbutamol concentration-response curve was biphasic: the maximum positive inotropic effect was significantly reduced by almost 50% (Table 2) , with no changes in its EC 50 , and was followed by a negative inotropic Values are means Ϯ SE of n different muscles. AACOCF3, arachidonyl trifluoromethyl ketone. Abs, absence of the component. *Different from control (P Ͻ 0.05).
effect (EC 50 of 25.1 Ϯ 6.6 nM, 10 times lower than that observed in papillary muscles from control guinea pigs). Increasing ICI-118551 concentration to 400 nM further reduced the positive inotropic effect and increased the amplitude of the negative component of the concentration-response curve (Table 2) . Thus ICI-118551 has a dual action: it exerts a noncompetitive-like antagonism on the G s -mediated positive inotropic effect occurring at low concentrations and allows salbutamol to activate at higher concentrations a second signaling pathway leading to a negative inotropic effect.
Since the slope of the modified Schild's equation for noncompetitive antagonism (2) was far below unity (0.31; pDЈ 2 value of 7.31), the ICI-118551 effect (decrease of the positive inotropic effect of salbutamol) is not truly noncompetitive.
These unexpected results strongly suggest the existence of an equilibrium between two active forms of the ␤ 2 -adrenocep- Role of endogenous catecholamines. Because we noted that the biphasic inotropic effect in response to ␤ 2 -adrenoceptor agonists was more consistently obtained during periods in which guinea pigs presented a higher L-type calcium current density than usual (which was also less sensitive to isoproterenol; unpublished observations), we hypothesized that the basal phosphorylation level due to circulating endogenous catecholamines was of importance. To assess this point, responses to salbutamol of right papillary muscles dissected from the heart of control and catecholamine-depleted guinea pigs were compared. In catecholamine-depleted guinea pigs, the response to increasing concentrations of salbutamol in the presence of 200 nM atenolol was overall a positive inotropic effect that appeared to be triphasic (Fig. 4) : contraction amplitude first significantly increased (ϩ9.9 Ϯ 2.9% at 2 nM; n ϭ 7), then decreased (ϩ4.9 Ϯ 2.9% at 60 nM) and increased again to a maximum of ϩ22.8 Ϯ 9.8% at 6 M. Adjusting a double logistic equation to the data (concentrations up to 60 nM) gave an EC 50 of 0.47 Ϯ 0.17 nM for the positive inotropic effect (ϩ15.0 Ϯ 2.4%) and an EC 50 of 5 nM for the decreasing limb of the curve, a value that was similar to that obtained in control animals (4.9 nM, Fig. 4 ). Thus our results strongly suggest that the ability of salbutamol to induce a positive or a negative inotropic effect depends on the basal phosphorylation state of papillary muscles and that phosphorylation is a prerequisite to the negative inotropic effect.
Roles of PKA and phosphatases. Since the classical signaling pathway of ␤ 2 -adrenoceptor activation involves the adenylate cyclase/cAMP activation of PKA, the potential role of this enzyme was assessed with H-89, one of its classical inhibitors. In the presence of 20 M H-89 (which markedly depressed contraction amplitude by 50.5 Ϯ 4.0%; n ϭ 5), salbutamol induced a monophasic negative inotropic effect that was considerably reduced compared with control (Fig. 5A) . Fig. 3 . A: inhibitory effect of acetylcholine on the positive inotropic effect induced by 50 nM isoproterenol (Iso) in papillary muscles isolated from control (hatched bars, n ϭ 7) and pertussis toxin (PTX)-treated (filled bars, n ϭ 8) guinea pigs. *Different from control muscles, P Ͻ 0.05. B: mean concentration-response curves to salbutamol of PTX-treated guinea pig papillary muscles in the presence of 4 M atenolol and in the absence (E, n ϭ 4) or presence of 40 nM (F, n ϭ 4) or 400 nM (OE, n ϭ 4) ICI-118551. Smooth lines represent nonlinear adjustment to the mean data points of Eq. 1 or Eq. 3 with the parameters given below, and vertical bars represent ϮSE. Control: Amax ϭ 105.82%, EC50 ϭ 0.10 nM, p ϭ 1; 40 nM ICI-118551: Amax ϭ 103%, Amin,1 ϭ 100%, Amin,2 ϭ 99.80%, EC50,1 ϭ 0.062 nM, EC50,2 ϭ 25.11 nM, p ϭ 1; 400 nM ICI-118551: Amax ϭ 102%, Amin,1 ϭ 100%, Amin,2 ϭ 96.51%, EC50,1 ϭ 0.072 nM, EC50,2 ϭ 52.44 nM, p ϭ 1. * , #Different from control and 40 nM ICI-118551 data points, respectively, with P Ͻ 0.05. The negative inotropic effect occurring at high concentrations (with an EC 50 in the submicromolar range) was abolished. At low concentrations, the residual negative inotropic effect represented ϳ50% of that observed in control conditions (Table  3) , with no significant change in the EC 50 (from 11.0 Ϯ 4.5 nM to 14.0 Ϯ 3.7 nM; n ϭ 5). Thus PKA activation appeared to play a central role in the salbutamol-induced negative inotropic effect.
As previously reported (12) , PKA could induce phosphorylation of the ␤ 2 -adrenoceptor, switching its coupling from G s to G i , and thus could activate G i -dependent signaling pathways leading to a negative inotropic effect. As a consequence, dephosphorylation by phosphatases that have been shown to form complexes with ␤ 2 -adrenoceptors (3, 13, 44, 48) should modulate the response to salbutamol. To test this hypothesis, the same experiments were carried out in the presence of okadaic acid, an inhibitor of protein phosphatases 1 and 2A. Figure 5B shows that in the presence of 1 M okadaic acid, the concentration-dependent negative inotropic effect induced by salbutamol is maintained, but with a significant leftward shift of the EC 50 of the second component by a decade, from 1.2 Ϯ 0.4 M to 149.5 Ϯ 73.4 nM (n ϭ 4; Table 3 ). Thus phosphatases modulate the sensitivity of the ␤ 2 -adrenoceptor to salbutamol, as expected.
Involvement of PI3K/cPLA 2 /arachidonic acid pathway. In rat ventricular myocytes, PI3K blockade enhances the contractile responses to zinterol, a ␤ 2 -adrenoceptor agonist, in a PTX-sensitive manner, showing that PI3K functionally restricts the ␤ 2 -adrenoceptor-mediated cAMP/PKA signaling (26) . We therefore tested the implication of PI3K in the negative inotropic effect of salbutamol, which we showed to depend on G i . In the presence of 100 nM wortmannin, the inotropic effect occurring at low concentrations was statistically reduced by almost 50% with no changes in the EC 50 (see Table 3 and Fig. 6Aa ). In the presence of a higher concentration of wortmannin (400 nM; Fig. 6Ab ), it was reversed to a positive one with an EC 50 identical to that of the negative inotropic effect obtained under control conditions (Table 3) . The negative inotropic effect occurring at higher concentrations remained unaffected. Thus, PI3K activation is also implicated in the negative inotropic effect occurring at low concentrations.
Several studies (e.g., Refs. 17, 35, 46, 49) have reported that PI3K is a key enzyme upstream of cPLA 2 , which has been shown to be involved in ␤ 2 -adrenoceptor signaling in chicken (42) , human (43) , and rat (1) hearts. Since cPLA 2 activation limits in these preparations the ␤ 2 -adrenoceptor agonistinduced intracellular calcium (Ca i ) and contractile responses via the adenylate cyclase/PKA pathway, we tested its implication in the salbutamol-induced negative inotropic effect. As shown in Fig. 6B , inhibition of cPLA 2 with its specific inhibitor AACOCF 3 (10 M) revealed a positive inotropic effect of salbutamol occurring at low concentrations (ϩ5.9 Ϯ 2.6% at 60 nM; n ϭ 4) with an EC 50 value of 2.4 Ϯ 0.9 nM, identical to that obtained under control conditions (2.9 Ϯ 0.6 nM; Table 3 ). This effect is more pronounced than that in the presence of 400 nM wortmannin (Fig. 6Ab) . The amplitude of the negative inotropic effect occurring at higher concentrations was significantly increased (by ϳ85%) from Ϫ4.8 Ϯ 0.3% to Ϫ9.0 Ϯ 0.7%, with no significant modification in the EC 50 (Table 3 ). This suggests that cPLA 2 might likely induce a negative feedback control on the signaling pathway involved for that component. Thus, besides PI3K, cPLA 2 activation is also necessary for salbutamol to induce a negative inotropic effect at low concentrations (in the nanomolar range).
cPLA 2 hydrolyzes glycerophospholipids of the membrane to liberate arachidonic acid (AA), which is then metabolized by three major pathways: cyclooxygenases (COX), lipoxygenases, and cytochrome P-450. In the presence of 10 M indomethacin, an inhibitor of COX-1 and COX-2, only the negative inotropic effect of salbutamol occurring at low concentrations was strongly reduced by Ͼ70% (from Ϫ7.2 Ϯ 0.4% to Ϫ2.1 Ϯ 0.2%; n ϭ 9; Fig. 6C and Table 3 ). This suggests that at least one of the COX-generated AA metabolites might be involved in the negative inotropic effect of salbutamol. In contrast, the lipoxygenase pathway does not seem to be involved in the negative inotropic effect of salbutamol, because experiments carried out in the presence of 30 M NDGA, an inhibitor of lipoxygenases, showed no significant alterations in the concentration-response curves to salbutamol (data not shown).
Central role of nitric oxide synthase activation. NO is a ubiquitous signaling molecule that is well known to attenuate the chronotropic and inotropic response to ␤-adrenoceptors agonists in the heart (see, e.g., Refs. 4, 5; for review, see Ref. 10). We therefore investigated its potential role by comparing responses to salbutamol in the presence and absence of L-NAME, a nonselective inhibitor of nitric oxide synthase (NOS). In the presence of 100 M L-NAME (Fig. 7) , the negative inotropic effects occurring at low and high concentrations of salbutamol were considerably reduced and no more significant compared with the basal contraction amplitude.
Thus our results clearly demonstrate that salbutamol-induced negative inotropic effect depends on NO synthesis. It should be noted that 100 M L-NAME alone induced a positive inotropic effect of ϩ10.6 Ϯ 3.0% (n ϭ 10), indicating a constitutive activity of NOS in guinea pig papillary muscles.
DISCUSSION
The main result of our study is that short-acting ␤ 2 -adrenoceptor partial agonists induce an unexpected NO-mediated biphasic negative inotropic effect in guinea pig right papillary muscles. Low concentrations of agonists activate a G i -dependent PKA/PI3K/cPLA 2 pathway leading to NO release via the AA/COX pathway. High concentrations likely induce a PKAdependent direct or indirect NO release negatively controlled by cPLA 2 . These findings indicate that the ␤ 2 -adrenoceptors found mostly by binding studies in the guinea pig heart in relatively small amounts are indeed functional, but in an unexpected way. 
Negative inotropic effect of ␤ 2 -adrenoceptor activation.
Concentration-response curves to salbutamol, terbutaline, and procaterol built in the presence of atenolol have revealed that the activation of ␤ 2 -adrenoceptors leads to a negative inotropic effect that is masked by the concomitant positive inotropic effect induced by ␤ 1 -adrenoceptor activation. A nonspecific activation of ␤ 3 -adrenoceptors that are known to induce a negative inotropic effect (for review, see Ref. 19 ) was ruled out since a ␤ 3 -adrenoceptor antagonist had no effect. SR59230A was used at a concentration of 200 nM since at a higher concentration it lacks specificity toward ␤ 3 -adrenoceptors (IC 50 of 408 and 648 nM for ␤ 1 -and ␤ 2 -adrenoceptors, respectively; Ref. 33) . On the other hand, involvement of ␤ 2 -adrenoceptors was confirmed by the effect of a low concentration (40 nM) of ICI-118551 (see below), a specific antagonist of these receptors.
This negative inotropic effect induced by ␤ 2 -adrenoceptor activation is surprising. As shown in several studies, the expected inotropic effect is a positive one, resulting from the classical coupling of ␤ 2 -adrenoceptors to the G s protein, leading to activation of the adenylate cyclase/PKA pathway. However, Xiao et al. (55) have demonstrated that ␤ 2 -adrenoceptors from rat ventricular myocytes are simultaneously coupled to G s and G i proteins. The PKA-mediated coupling to G i protein (12) activates signaling pathways shown to confine the ␤ 2 -adrenoceptor/PKA signaling to restricted subsarcolemmal spaces (see, e.g., Refs. 11, 26, 56) and to limit the positive inotropic effect that should normally result from their activation. Our results are in agreement with such a dual coupling to G s and G i proteins since in papillary muscles from PTX-pretreated guinea pigs salbutamol induced only a positive inotropic effect. Thus the negative inotropic effect observed in muscles from control animals suggests a preponderant activation of G i -dependent signaling pathways, consistent with our working hypothesis. Moreover, the biphasic nature of the negative inotropic effect indicates that ␤ 2 -agonists can activate two signaling pathways with different threshold and sensitivity.
Effect of ICI-118551. Unusual also are the effects of the selective ␤ 2 -adrenoceptor antagonist ICI-118551, both in control and in PTX-treated muscles. Indeed, in PTX-treated muscles, the maximum amplitude of the salbutamol-induced positive inotropic effect decreased with increasing concentrations of ICI-118551, with no changes in its EC 50 (noncompetitivelike antagonism). This reduction in amplitude was concomitant with the apparition of a negative inotropic effect of salbutamol for concentrations above 2 nM, whose amplitude increased with ICI-118551 concentration. A noncompetitive-like effect of ICI-118551 has already been reported to occur in two cell lines (24) with a low level of expression of ␤ 2 -adrenoceptors: BC3H1 cells (endogenous constitutively active ␤ 2 -adrenoceptors, 77.9 fmol/mg protein) and a stable Chinese hamster ovary (CHO) cell line (transfected with the human ␤ 2 -adrenoceptor, 50 fmol/mg protein). These authors have suggested that the noncompetitive-like effect of ICI-118551 might be due to its interaction with different affinity states of the receptor. Although the control of the contractile state is a multistep process resulting from the activation of numerous signaling pathways, our results might suggest, as in these studies, the possible existence of an equilibrium between active conformations of the receptor that could be induced and displaced by low concentrations of ICI-118551. The observation of the inotropic consequences of such an hypothetical equilibrium is probably facilitated by the low reserve of ␤ 2 -adrenoceptors in the guinea pig heart (38), as in BC3H1 cells (24) . Although experiments at the molecular level are needed to clearly demonstrate the existence of different active conformations of the ␤ 2 -adrenoceptor in equilibrium, our hypothesis would also explain the paradoxical effect of low and high concentrations of ICI-118551 on the first negative component of the inotropic effect of salbutamol in control muscles. This component has an EC 50 in the nanomolar range, as expected for activation of ␤ 2 -adrenoceptors (i.e., Refs. 9, 57) and results from the activation of a dominant G i -dependent signaling pathway, as can be concluded from the experiments in muscles from PTX-treated guinea pigs. Experiments carried out in the presence of 40 nM ICI-118551 strongly suggest that this first component results from the activation of ␤ 2 -adrenoceptors. However, depending on the concentration of antagonist used, nanomolar concentrations of salbutamol can induce either a positive (G s mediated) or a negative (G i mediated) inotropic effect, a result consistent with an equilibrium between G s -coupled and G i -coupled conformations of the receptor (28, 29) .
Our results strongly suggest that the second component of the negative inotropic effect might result from salbutamol acting on a specific conformation of ␤ 2 -adrenoceptors. First, it can be observed in muscles from PTX-treated guinea pigs once the receptor has acquired a particular conformation in the presence of 40 nM ICI-118551, a concentration specific for the ␤ 2 -adrenoceptors. Second, a concentration of 400 nM ICI-118551, sufficient to block 99% of the receptors, induced a ϳ27 times increase in its EC 50 in control muscles (leading to an apparent pA 2 of ICI-118551 of 7.82). As already stated in RESULTS, an additional effect of ICI-118551 on ␤ 1 -adrenoceptors is probably irrelevant since the concentration of atenolol used (4 M) is already sufficient to induce Ͼ95% block of these receptors. 
Signaling pathways involved.
Our results show a key role of phosphorylation processes in mediating the negative inotropic effect of salbutamol: 1) in catecholamine-depleted animals, the inotropic effect is on the overall a positive one; 2) blockade of PKA with H-89 resulted in a strong reduction of the first component (EC 50 in the nanomolar range) and the suppression of the second component (EC 50 in the submicromolar range); and 3) when dephosphorylation processes are prevented by okadaic acid, the sensitivity to high concentrations of salbutamol is increased. The high concentration of H-89 used (20 M) was required to block most of the inotropic response to isoproterenol in our experimental conditions. KT-5720, another PKA inhibitor, was not used since it was inefficient at concentrations up to 50 M. Although we cannot exclude that H-89 might also have affected other protein kinases besides PKA (14, 32), we can nevertheless assume that PKA activation is likely underlying both negative inotropic effects.
Our results also support a key role of NO in the two components of the negative inotropic effect, since they are almost suppressed in the presence of L-NAME. As previously reported, ␤-adrenoceptors activation can induce NO release (e.g., Refs. 15, 27) . Moreover, NOS activity is regulated by phosphorylation-dephosphorylation processes (for review, see Ref. 34) , like the inotropic effect we observed. Although specific NOS inhibitors were not used, a possible candidate is endothelial NOS (NOS3), which has been shown to be colocalized in caveolae with L-type calcium channels, ␤ 2 -adrenoceptors, caveolin 3, and adenylate cyclase (see, e.g., Ref. 41 ; for review, see Ref. 34) . Because of the multicellular nature of papillary muscles, the exact origin of the NO released (endothelial cells, fibroblasts, or myocardium) is uncertain and will require further investigation.
As shown and discussed above, the two NO-dependent components of the negative inotropic effects are differentially affected by the inhibitors used. These results strongly support activation of at least two different pathways leading to NO release. Figure 8 summarizes the signaling pathways that are likely involved in the ␤ 2 -adrenoceptor activation induced by salbutamol in guinea pig right papillary muscles, as deduced from the results presented in this study and from data available in the literature. At low concentrations of salbutamol, ␤ 2 -adrenoceptor coupling to G s leads to activation of PKA and to an increase of intracellular calcium. The positive inotropic effect that would normally occur is overridden by simultaneous activation of cPLA 2 by PI3K and Ca i , leading to NO synthesis via AA metabolites produced by COX (resulting in the negative inotropic effect with an EC 50 in the nanomolar range). Simultaneously, PKA also phosphorylates the receptor and induces its coupling to G i . This coupling contributes also to the activation of cPLA 2 [as described by Aït-Mamar et al. (1) ] and to its positive control by PI3K. Because we found that the negative inotropic effect occurring at higher salbutamol concentrations (EC 50 in the submicromolar range) was sensitive only to H-89, L-NAME, and AACOCF 3 , we hypothesize that PKA-dependent phosphorylation of the receptor leads to activation of NOS independently of the G i -dependent PI3K/cPLA 2 pathway and that cPLA 2 exerts a negative control on this second pathway leading to NOS activation. Whether NO directly decreases Ca i or acts via activation of the guanylate cyclase/cGMP/PKG pathway awaits further studies. It would be also of interest to investigate the possible cross talk between cPLA 2 , COX, and NOS.
Phosphorylation of the COOH-terminal tail of ␤ 2 -adrenoceptors (see, e.g., Refs. 21, 47) has been reported to activate a G i protein-independent signaling pathway in mouse embryonic fibroblasts (51): MAPK activation following ␤ 2 -adrenoceptors activation is biphasic, the agonist inducing itself a dosagedependent switch from a G␣ s protein-coupled (activation of MAPK pathway, EC 50 Ϸ 1 nM isoproterenol) to a G proteinindependent signaling (tyrosine kinase Src-dependent pathway, EC 50 Ϸ 1 M isoproterenol). It is noteworthy that the EC 50 values reported in this study are very similar to those determined for the ␤ 2 -agonists-induced negative inotropic effect we found. Whether or not such a pathway exists in the guinea pig heart and is responsible for the second component of the negative inotropic effect remains to be determined.
Because the inotropic effects of ␤ 2 -agonists we found are small and unusual (negative ones), require ␤ 1 -adrenoceptors to be blocked by atenolol, and show a peculiar unexpected sensitivity to ICI-118551, this might explain why ␤ 2 -adrenoceptors have mostly been considered in the literature so far as nonfunctional in the guinea pig heart (see, e.g., Refs. 16, 23, 40). However, other studies have given evidence of a functionality of these receptors in the guinea pig heart: Lemoine et al. (31) and Voss et al. (52) have respectively reported a positive chronotropic effect of fenoterol and TA2005 in atrium, and antibodies raised against the second extracellular loop of the human ␤ 2 -adrenoceptor have been shown to increase the L-type calcium current in ventricular heart cells (30, 36) .
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